Immunovant Inc (IMVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 03-2021 | 03-2020 | 03-2019 | 03-2018 | 03-2007 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 400,146 | 100,571 | 6,985 | N/A | N/A |
| Receivables | 1,144 | 3,045 | 2,962 | N/A | N/A |
| TOTAL | $409,006 | $109,076 | $12,579 | $N/A | $N/A |
| Non-Current Assets | |||||
| PPE Net | 201 | 65 | 54 | N/A | N/A |
| Other Non-Current Assets | 3,282 | 246 | 1,195 | 0 | 0 |
| TOTAL | $3,483 | $311 | $1,249 | $N/A | $N/A |
| Total Assets | $412,489 | $109,387 | $13,828 | $N/A | $N/A |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,432 | 4,380 | 264 | 0 | 0 |
| Accrued Expenses | 15,160 | 10,938 | 6,225 | N/A | N/A |
| TOTAL | $18,771 | $15,318 | $6,489 | $N/A | $N/A |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 2,238 | 0 | 0 | 0 | 0 |
| TOTAL | $2,238 | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $21,009 | $15,318 | $6,489 | $N/A | $N/A |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 97,977 | 81,812 | 14,375 | N/A | N/A |
| Common Shares | 10 | 5 | 1 | N/A | N/A |
| Retained earnings | -198,657 | -91,226 | -24,838 | N/A | N/A |
| Other shareholders' equity | -298 | -16 | 346 | 0 | 0 |
| TOTAL | $391,480 | $94,069 | $7,339 | $N/A | $N/A |
| Total Liabilities And Equity | $412,489 | $109,387 | $13,828 | $0 | $0 |